| I. COMMENCED TRADING IN DECEMBER | ||||||||
| Company (Symbol) # |
Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M) @ |
Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M) % |
| INITIAL OFFERINGS | ||||||||
|
Hybrigenics SA (France; PARIS: ALHYG) 1 |
ND | 12/26** | 0.708S and W | €8.70 | 10.1 | N/A | €6.16 ($23.8) | E87.9 ($130) |
|
NovaBayPharmaceuticals Inc. (AMEX:NBY) |
2/14 | 10/26* | 5S | $4 | 21.1 | Dundee Securities Inc. Desjardins Sec. (co-lead) Blackmont Capital Dawson James Sec. |
$20 | $84.4 |
| * NovaBay's IPO was completed in October but not listed in that month's chart. Total: $43.8M Number of IPOs in December: 2Average value of December IPOs: $21.9 Number of IPOs in 2007: 41Total raised in IPOs in 2007: $1,858.36M Average value of IPOs in 2007: $45.33M | ||||||||
| FOLLOW-ON OFFERINGS | ||||||||
| Company (Symbol) # |
Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M) @ |
Lead, Other Underwriters | Gross (M) | Post-Offering Market Cap (M) % |
|
Anesiva Inc. (ANSV) 2 |
12/13 | 12/26 | 12.3S | $4.05 | 40.3 | Pacific Growth Equities Broadpoint Capital Inc. Fortis Securities LLC |
$49.8 | $163.2 |
| EpiCept Corp. (EPCT) | 10/14 | 12/4 | 3.3S and W for 1.7S | $1.50 | 46.8 | Rodman & Renshaw | $4.95 | $70.2 |
|
Total: $54.75M Number of follow-on offerings in December: 2 Average value of December follow-ons: $27.38M Number of follow-on offerings in 2007: 51 Total raised in follow-ons in 2007: $2,910.24M Average value of follow-ons in 2007: $57.06M | ||||||||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. AMEX = American Stock Exchange 1 Hybrigenics went public on the Alternext market of the Euronext Paris stock exchange. 2 Includes Anesiva's overallotment option: 1.2M shares. | ||||||||
| II. FILED AND PENDING | ||||||
| Company (Symbol/ Proposed Symbol) #* |
Date Filed | Shares/Units (M) | PriceRange |
Shares Out (M) @ |
Lead, Other Underwriters | Value (M) |
| INITIAL OFFERINGS | ||||||
|
AegerionPharmaceuticals Inc. (AEGR) |
11/21/07 | N/A | N/A | N/A | Piper Jaffray Thomas Weisel Partners (co-lead) Lazard Capital Markets Collins Stewart LLC |
$86 |
|
Anacor Pharmaceuticals Inc. (ANAC) |
8/31/07 | N/A | N/A | N/A | Morgan Stanley & Co. Inc. Cowen & Co. LLC (co-lead) Pacific Growth Equities LLC Needham & Co. LLC |
$57.5 |
| Archemix Corp.(ARCH) | 7/25/07 | N/A | N/A | N/A | Banc of America Securities Bear, Stearns & Co. Inc. Cowen and Co. |
$69 |
|
Bioheart Inc. (BHRT) 1 |
2/13/07 | 3.575S | $14-$16 | 16.9 | BMO Capital Markets Corp. Janney Montgomery Scott (co-lead) Merriman Curhan Ford & Co. |
$53.6 |
| Biolex Inc.(BLEX) | 8/14/07 | N/A | N/A | N/A | Lehman Brothers Inc. Deutsche Bank Securities (co-lead) Leerink Swann & Co. Inc. |
$70 |
| ChemocentryxInc. (CCXI) | 11/12/07 | N/A | N/A | N/A | Credit Suisse Securities LLC Cowen and Co. Leerink Swann Lazard Capital Markets |
$57.5 |
| Elixir Pharmaceuticals Inc. (ELXR) | 9/24/07 | 5S | $14-$16 | 143.5 | Credit Suisse Securities LLC Pacific Growth Equities Leerink Swann LLC |
$75 |
| Insys Therapeutics Inc. (INRX) | 8/20/07 | N/A | N/A | N/A | Banc of America Securities UBS Investment Bank (co-lead) JMP Securities Natixis Bleichroeder |
$86.25 |
|
Light Sciences Oncology Inc. (LSON) |
4/21/06 | 5.25S | $14-$16 | 18.5 | Cowen & Co. Wachovia Securities (co-lead) Jefferies & Co. Thomas Weisel Partners |
$78.75 |
|
Merrion Pharmaceuticals Ltd. (MERR) 2 |
4/3/07 | 4S | $6-$7 | 15 | Punk, Ziegel & Co. Goodbody Stockbrokers Stanford Group Co. |
$26 |
| MonoSol Rx Inc.(MSRX) | 5/14/07 | 4S | $16-$18 | N/A | Cowen and Co. CIBC World Markets Susquehanna Financial |
$68 |
|
Peplin Inc.(PLIN) 3 |
8/10/07 | N/A | N/A | N/A | Merrill Lynch & Co. Cowen & Co. LLC Thomas Weisel Partners Leerink Swann & Co. Merrill Lynch International Wilson HTM |
$75 |
| Prometheus Laboratories Inc. | 12/19/07 | N/A | N/A | N/A | Goldman Sachs & Co. Credit Suisse (co-lead) |
$100 |
| RXi Pharmaceuticals Corp. (RXIP;unit of CytRx Corp.) | 10/30/07 | 10.8S | N/A | N/A | N/A | N/A |
| Talecris Biotherapeutics Holdings Corp. (TLCR) | 7/30/07 | N/A | N/A | N/A | Morgan Stanley Goldman Sachs & Co. J.P. Morgan |
$1B |
| Xanodyne Pharmaceuticals Inc. (XANO) | 11/9/07 | N/A | N/A | N/A | Morgan Stanley Deutsche Bank (co-lead) RBC Capital Markets Natexis Bleichroeder |
$86.25 |
| XDx Inc. (XDXI) | 10/24/07 | N/A | N/A | N/A | J.P. Morgan Securities Inc. Morgan Stanley & Co. (co-lead) Piper Jaffray & Co. JMP Securities LLC |
$86.3 |
| FOLLOW-ON OFFERINGS | ||||||
|
Bioxel Pharma Inc. (Canada; CDNX:BIP) 4 |
7/9/07 | N/A | N/A | N/A | Paradigm Capital Laurentian Bank Sec. |
N/A |
| Chemokine Therapeutics Corp. (Canada;TSX:CTI; OTC BB: CHKT) | 5/30/07 | N/A | N/A | N/A | GMP Securities | $25 |
| WITHDRAWN AND POSTPONED | ||||||
|
Akela Pharma Inc. (Canada; TSX:AKL; AKLA) 5 |
10/12/07 12/20/07 |
5.3S | $6-$8 | 17 | Lazard Capital Markets Oppenheimer & Co. Broadpoint |
$37.1 |
| Precision Therapeutics Inc. (PRCN) 6 | 8/24/07 12/7/07 |
N/A | N/A | N/A | JP Morgan Piper Jaffray (co-lead) JMP Securities |
$80.5 |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. N/A = Not available, applicable or reported. CDNX = Canadian Venture Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. 1 Bioheart's overallotment option: 536,250 shares. 2 Merrion plans to list American depositary shares on Nasdaq and ordinary shares in a secondary listing on the Irish Enterprise Exchange, both under the ticker "MERR." 3 Peplin Ltd., of Australia, established the U.S. subsidiary to facilitate an IPO. 4 Bioxel filed for a Canadian offering of units consisting of one common share and one-half of a common share purchase warrant. 5 Akela terminated plans for an IPO in the U.S. due to unfavorable market conditions for small and micro-cap companies. 6 Precision's IPO was set aside after announcing a planned merger with Oracle Healthcare Acquisition Corp. | ||||||